BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - FRA:BRM - US1101221083 - Common Stock
40.41 EUR
-2.32 (-5.43%)
Overall BRM gets a fundamental rating of 6 out of 10. We evaluated BRM against 54 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BRM get a neutral evaluation. Nothing too spectacular is happening here. BRM is valued quite cheap, while showing a decent growth score. This is a good combination! BRM also has an excellent dividend rating. With these ratings, BRM could be worth investigating further for value and dividend investing!.
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
BRM had a positive operating cash flow in the past year.
In multiple years BRM reported negative net income over the last 5 years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BRM (6.23%) is comparable to the rest of the industry.
The Return On Equity of BRM (32.55%) is better than 79.63% of its industry peers.
With a decent Return On Invested Capital value of 16.42%, BRM is doing good in the industry, outperforming 77.78% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BRM is below the industry average of 14.87%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(16.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 16.42% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
With a Profit Margin value of 12.57%, BRM perfoms like the industry average, outperforming 53.70% of the companies in the same industry.
BRM's Operating Margin of 33.51% is amongst the best of the industry. BRM outperforms 81.48% of its industry peers.
In the last couple of years the Operating Margin of BRM has declined.
The Gross Margin of BRM (73.15%) is better than 61.11% of its industry peers.
In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
The number of shares outstanding for BRM has been reduced compared to 1 year ago.
BRM has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BRM is higher compared to a year ago.
2.2 Solvency
BRM has an Altman-Z score of 2.16. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
BRM has a worse Altman-Z score (2.16) than 62.96% of its industry peers.
The Debt to FCF ratio of BRM is 3.20, which is a good value as it means it would take BRM, 3.20 years of fcf income to pay off all of its debts.
BRM's Debt to FCF ratio of 3.20 is fine compared to the rest of the industry. BRM outperforms 61.11% of its industry peers.
A Debt/Equity ratio of 2.41 is on the high side and indicates that BRM has dependencies on debt financing.
BRM has a worse Debt to Equity ratio (2.41) than 81.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.16 |
ROIC/WACC2.07
WACC7.93%
2.3 Liquidity
BRM has a Current Ratio of 1.27. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BRM (1.27) is worse than 61.11% of its industry peers.
A Quick Ratio of 1.17 indicates that BRM should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.17, BRM is doing good in the industry, outperforming 68.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 460.68% over the past year.
BRM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
BRM shows a small growth in Revenue. In the last year, the Revenue has grown by 1.26%.
BRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
BRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.26% yearly.
BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.17% yearly.
EPS Next Y472.54%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
EPS Next 5Y35.26%
Revenue Next Year-0.35%
Revenue Next 2Y-4.29%
Revenue Next 3Y-3.28%
Revenue Next 5Y-5.17%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 7.15, the valuation of BRM can be described as very cheap.
BRM's Price/Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 94.44% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.89, BRM is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 7.71, the valuation of BRM can be described as very cheap.
Based on the Price/Forward Earnings ratio, BRM is valued cheaper than 92.59% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, BRM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.15 | ||
| Fwd PE | 7.71 |
4.2 Price Multiples
88.89% of the companies in the same industry are more expensive than BRM, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 96.30% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.25 | ||
| EV/EBITDA | 6.31 |
4.3 Compensation for Growth
BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM's earnings are expected to grow with 73.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y131.12%
EPS Next 3Y73.23%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.10%, BRM is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.89, BRM pays a better dividend. On top of this BRM pays more dividend than 92.59% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.36, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.1% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
82.81% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
BRM's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP82.81%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
FRA:BRM (11/14/2025, 7:00:00 PM)
40.41
-2.32 (-5.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.84%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap82.25B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.88
Price Target45.62 (12.89%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.1% |
Yearly Dividend2.07
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)2.91%
PT rev (3m)0.26%
EPS NQ rev (1m)4.98%
EPS NQ rev (3m)4.24%
EPS NY rev (1m)-0.88%
EPS NY rev (3m)-1.9%
Revenue NQ rev (1m)2.44%
Revenue NQ rev (3m)2.35%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)3.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.15 | ||
| Fwd PE | 7.71 | ||
| P/S | 1.99 | ||
| P/FCF | 6.25 | ||
| P/OCF | 5.75 | ||
| P/B | 5.15 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.31 |
EPS(TTM)5.65
EY13.98%
EPS(NY)5.24
Fwd EY12.97%
FCF(TTM)6.47
FCFY16.01%
OCF(TTM)7.03
OCFY17.39%
SpS20.31
BVpS7.84
TBVpS-10
PEG (NY)0.02
PEG (5Y)N/A
Graham Number31.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 16.42% | ||
| ROICexc | 21.58% | ||
| ROICexgc | 109.99% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.16 |
F-Score6
WACC7.93%
ROIC/WACC2.07
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y472.54%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year-0.35%
Revenue Next 2Y-4.29%
Revenue Next 3Y-3.28%
Revenue Next 5Y-5.17%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.82%
EBIT Next 3Y49.42%
EBIT Next 5Y23.49%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
What is the valuation status for BRM stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 5 / 10.
How financially healthy is BRISTOL-MYERS SQUIBB CO?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 472.54% in the next year.